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Welcome to Fusion
 As part of our commitment to fostering student 
interest in research, the William Beaumont Medical 
Research Honors Society at The George Washington 
University School of Medicine and Health Sciences 
is proud to introduce the 2014 edition of Fusion — a 
student-run research journal that serves as a forum for 
students to share their research experiences with the 
GW medical community. 
This year’s edition focuses on the theme of putting 
basic science research into clinical practice. Medicine 
is an incredibly dynamic and rapidly evolving field. At 
the same time, basic science is identifying new molec-
ular pathways, genetic polymorphisms in disease, and 
targeted pharmaceutical therapies at an impressive 
rate. While these developments are aimed at advancing 
the medical field, the integration of these innovations 
into clinical practice also poses a unique challenge for 
today’s healthcare professionals.
Never before has the collaboration and coordi-
nation of researchers and health care providers been 
more important. As future health care professionals 
it is imperative that we seek to continue to integrate 
these dynamic aspects into our own practice. However, 
learning these skills most often requires us to immerse 
ourselves in enriching experiences outside the class-
room, and it is these endeavors that Fusion highlights. 
This publication features a “fusion” of clinical, basic 
science and public health research, ref lecting the 
experiences of a number of enthusiastic and dedicated 
members of the GW SMHS student body. We hope 
that as you enjoy reading the following articles you are 
inspired to seek opportunities that will help strengthen 
your own skills as future healthcare professionals.
Lastly, we would like to thank all of our authors and 
artists who help to make Fusion a great success each 
year. We also extend our many thanks to the Office of 
the Deans for their generous support, and to the staff at 
SMHS Communications and Marketing for helping to 
















Jeffery Shu-Chieh Yu 
Kelly Zhang
Dear GW Community and fellow research enthusiasts,
The brain is the most complicated 
organ in the human body. Anatomical 
and physiological circuits provide 
us with the ability to communicate, 
experience emotion, learn, create 
memories, and much more. 
 
The cover image was created 
by second-year medica l student 
Cate Haring, while she was con-
ducting neuroscience research at 
Children’s National Health System 
in Washington, D.C. Over the course 
of her research Haring was struck by 
the beauty, complexity, and mystery of 
neural circuits involved in both health 
and disease. Novel imaging techniques 
and molecular diagnostic studies are 
beginning to shed light on the patho-
genesis of neurological conditions, 
however there remains much to be 
discovered. Haring used cherry blos-
soms in the cover image to represent 
the beauty she found in neural circuits 
and the current neuroscience research 
being conducted in Washington, D.C. 
Behind the acrylic painting is a repre-
sentation of neurons firing.
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In the 1960s and 1970s, equipped with of “first generation” tools 
of molecular biology — as well as classical biochemistry and the 
emerging discipline of “cell biology” — a whole generation of physi-
cians and scientists worked side-by-side to fight a “war” on cancer. 
The partnership was inspiring, and facilitated by medical education at 
the time. First- and second-year medical students were taught by the 
faculty members who were actually doing the research, and lectures 
often included the newest data from their own or other laboratories. 
This “hot off the bench” approach primed a whole generation of physi-
cians to be ready to apply insights of basic molecular biology not only 
to new diagnostic and therapeutic approaches to cancer, but also to 
new infectious diseases that arose 20 years later (HIV, SARS, Ebola 
virus), and the newer “genetic medicine” that crystalized following 
completion of the first-draft human genome sequence in the late 
1990s. This progress produced declines in mortality and morbidity 
due to cancers: now diagnosis, though serious, is not a shameful 
death sentence. New treatments provide multiple opportunities for 
intervention, and in some cases partial or even complete (as one can 
tell) cures. Neuroscientists view this nearly 60-year odyssey with 
admiration and a little bit of envy — if only we could report the same 
level of advance.
Serendipity and the Path to Discovery
Anthony-Samuel LaMantia, Ph.D.
The achievements of neuroscience seem slower, and clinical benefits have not yet been fully realized. When 
I was a student-scientist in the mid 1980s, there was a sense that a “first draft” of the rules of neuron structure, 
physiological function, and behavioral output by which nervous systems operated was nearly complete. The 
foundational work of the people who taught me about the nervous system — including Pasko Rakic, M.D., Ph.D.; 
Patricia Goldman Rakic, Ph.D.; and Gordon Shepherd, M.D., D.Phil,  at Yale University; Eric Kandel, M.D., 
and Dale Purves, M.D., at Cold Spring Harbor Laboratory; and many others — inspired me. The work we read 
by then leaders in the field such as Viktor Hamburger, Ph.D., and Nobel Prize winners Paul Greengard, Ph.D.; 
David Hubel, M.D.; Rita Levi Montalcini, M.D.; Erwin Neher, Ph.D.; Bert Sakmann, M.D.; Thomas Sudhof, 
M.D.; and Torstein Wiesel, M.D., gave me a sense that the inpenetrable gray lump that most biologists dismis-
sively considered the brain to be, could actually be studied using the same approaches as every other organ system. 
A second wave of revolutionary developments in molecular biology and genetics in the 1990s made it possible 
to consider the foundational “first draft” of how brains might work as a starting point to define molecular and 
cellular mechanisms that lead to devastating and intractable brain diseases.
At that moment I was fortunate enough to begin my scientific career as an independent investigator — first at 
Duke University, then at The University of North Carolina at Chapel Hill (UNC), and now at GW. I acquired a 
new tool kit of molecular biological approaches, with the help of my collaborator and friend Elwood Linney and 
several gifted students and post-docs. We focused on studying novel cell signaling mechanisms. We wished to 
understand how neural stem cells in the very early embryonic brain receive instructions that gave them identity. 
Surprisingly, the molecular mechanisms we identified were the same ones used for similar — though not iden-
tical — tasks that faces, hearts, and limbs together during early embryonic development. At this point, a truly 
fortunate event occurred: an academic psychiatrist, Jeffrey Lieberman, M.D. (who is, by the way, a GW Medical 
School alumnus) made me aware of a recently defined genetic disease — DiGeorge or 22q11 Deletion Syndrome, 
with an incidence rate of 1/3000 live births caused craniofacial, limb, and heart malformations recognized at 
birth (and, in the case of heart malformations, repaired shortly after birth to insure survival), followed by a 
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remarkable increase in early onset schizophrenia in many patients, autism and mood disorders in most others. 
Jeff Lieberman  and I recognized that the basic biology I had done and the clinical characteristics of this disorder 
likely had something to do with one another. With Jeff Lieberman’s instruction in the details of clinical brain 
disorders such as schizophrenia and autism, and using the tools of molecular biology — especially the ability to 
model human genetic disorders in the mouse — we defined how the genetic lesion that “causes” 22q11 Deletion 
Syndrome disrupts the shared mechanisms for heart, face, limb, and brain development. We also found, to our 
surprise, that this genetic disruption goes on to compromise development of neural circuits in the cerebral cortex 
that are essential for specific cognitive behaviors.  
The happy accident of meeting Lieberman occurred by chance during a scientific meeting (in Hawaii … 
doubly lucky for me!), and resulted in my migration from Duke to UNC where Lieberman was at the time. 
Jeff is now the chair of psychiatry at Columbia University, and Director of the New York State Psychiatric 
Institute. His work on the efficacy of antipsychotic drugs defines clinical practice, and his ongoing work on the 
biology of schizophrenia and other affective disorders is a model for translational research — he’s an inspiring 
GW alumnus. My goal, as I took on the role of founding director of the GW Institute for Neuroscience, was to 
facilitate many more similar “happy accidents” for GW clinicians, scientists, and students here in Foggy Bottom 
(sorry, no Hawaii trips). Together, we can define a new translational research enterprise in the neuroscience of 
brain diseases. Our efforts over the past four years are only now beginning to produce exciting results, but we 
are well positioned to drive full speed ahead— with fellow neuroscientists throughout the country and world — 
toward the seemingly bleak horizon of brain disease, and improve the outlook with new discoveries. Perhaps 60 
years from now, another GW faculty member, writing another faculty letter for the Beaumont  Society’s journal 
Fusion, will look back on our collective efforts at GW, and throughout the scientific community, in the same way 
that we now look back upon the beginning of the “war on cancer”: — an intrepid collaboration between physi-
cians and scientists — those already trained, and those in training — that defined a path to better outcomes for 
generations of patients yet to come. 
Newer “genetic medicine” that 
crystallized following completion of the 
first-draft human genome sequence in 
the late 1990s helped produce significant 
declines in mortality and morbidity due 
to cancer. Using those tools of molecular 
biology, today’s scientists could unlock 
similarly transformational discoveries in 
the world of neuroscience.
— Anthony-Samuel LaMantia, Ph.D. 
professor of pharmacology & physiology, and founding 
director of the GW Institute for Neuroscience
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TABLE 1:  Study Participants’ Characteristics and  
Laboratory Data$
Non-Overweight Group Intervention Group
Parameter Baseline 12 Months
Weight (kg) 65.7±2.1*** 101.2±2.5 94.9±2.7###
BMI (kg/m2) 22.2±0.4*** 33.9±0.7 31.5±0.7###
Blood pressure (mm Hg)
Systolic 114.1±1.7 118.6±1.7 117.3±1.7
Diastolic 68.7±1.2 69.0±1.1 68.5±1.2
Fat Mass (kg) 15.1±1.07*** 41.7±1.5 36.6±1.6###
TSH (ng/dL) 1.8±0.16 2.2± 0.2 1.9±0.2
Free T4 (ng/dL) 1.24±0.50** 1.12±0.02 1.09±0.03
Total T3 (ng/dL) 100.6±3.1** 112.7±3.1 101.8±2.6###
Reverse T3 (ng/mL) 0.33±0.03* 0.26±0.01 0.26±0.01
Leptin (ng/dL) 9.3±2.2*** 39.1±3.6 34.5±3.4
REE (kcal/24h) 1307.5±46.9*** 1634.5±47.8 1612.9±43.1
Body Composition Adjusted REE - - 1575.9±60.3
Comparison Control and Intervention Group at Baseline: *p<0.05, **p<0.01, ***p<0.001
Comparison Between Baseline and 12 Months: #p≤0.05, ##p<0.01, ###p<0.001
$Data Expressed as Mean±SEM
Obesity is a source of considerable 
morbidity and early mortality in the 
United States and is the result of a 
sustained imbalance between energy 
intake and energy expenditure (EE)1. 
Thyroid hormone (TH) and par-
ticularly tri-iodothyronine (T3) play 
a critical role in the modulation of 
Resting Energy Expenditure (REE) 
and substrate metabolism2. While 
dietary restriction has been shown to 
inhibit the Hypothalamus-Pituitary-
Thyroid axis by a fall in leptin, 
whether nutrient deficits impact on 
peripheral TH metabolism is less 
known. A better understanding of 
the interaction between moderate 
calorie restriction, weight loss, and 
TH homeostasis could produce valu-
able information on the adaptive (or 
maladaptive) response to dietary 
intervention.  
The action of TH in the target 
tissues is the result of a multi-level 
control system. This allows the pre-
cise time- and tissue-specific delivery 
of the hormonal signal via the inter-
action of T3, the active form of TH, 
with its nuclear receptor isoforms3. 
The pool of T3 is the net result of 
its secretion from the thyroid gland, 
the peripheral conversion of the pro-
hormone T4 into T3, and its degrada-
tion. Peripheral conversion of T4 into 
T3, achieved by the combined actions 
of the deiodinases type-1 and type-2 
(D1 and D2) is responsible in humans 
for a substantial component of the 
circulating and tissue pool of TH4.  
Forty-seven subjects BMI≥25≤45 
Kg/m2 a nd 30 non-over weight 
controls were enrolled into the study. 
Over weight subjects under went 
a one-year individualized calorie-
restricted diet (~600 Kcal/day deficit) 
and were encouraged to increase 
physical activity, achieving 5-10% 
weight loss. Various metabolic mea-
surements were performed at 0, 1.5, 
3, 6, 9, and 12 months.
The inter vention resulted in 
6.3±0.9 kg (6.5±1.0%) weight loss 
(Table 1). At baseline, TSH and 
T3 levels correlated significantly 
with fat mass. After weight loss, 
T3 decreased significantly (from 
112.7±3.1 to 101.8±2.6 ng/dL p<0.001) 
in the absence of significant changes 
Moderate Weight Loss is Sufficient to Affect  
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in TSH or free T4 (f T4). The 
decrease in serum T3 correlated 
with the decrease in weight. T3: fT4 
ratio (used as an index of peripheral 
conversion of TH) decreased sig-
nificantly in individuals who lost >5% 
body weight. After correcting T3 for 
changes in fat mass, the decrease 
from baseline remained statistically 
significant. Longitudinally, while 
TSH levels had a non-significant 
reduction, and fT4 levels showed 
a small but significant reduction 
(Figure 1 D, E), the decrease in T3 
was more robust (p=0.001) (Figure 
1C).  The decrease in serum T3 cor-
related with the decrease in weight 
(R=0.294, p<0.001). No statistically 
significant changes in reverse T3 
levels were observed over the course 
of the study (Figure 1F).
A relative inhibition of peripheral 
5’-deiodination of the pro-hormone 
T4 into T3 is likely responsible for 
some of the observed changes in the 
thyroid homeostasis, as indicated by 
the significant decrease in the T3:fT4 
ratio, a sensitive index of conversion 
of TH in the individuals who had a 
greater degree of weight loss5. Our 
results indicate that T3 levels closely 
correlate with individual nutritional 
status, and moderate weight loss 
results in a significant decrease in 
T3 with minimal changes in other 
thyroid hormone homeostasis param-
eters. The data suggest a decrease 
in peripheral conversion of the pro-
hormone T4 into its hormonally 
active metabolite T3 is at least in part 
responsible for the changes in thyroid 
hormone level. 
REFERENCES
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expenditure. Clin Endocrinol Metab. 
1984;13:581–595.
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The Thyroid: A Fundamental and Clinical 
Text. New York: Lippincott Williams & 
Wilkins; 2004.
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FIGURE 1: Longitudinal changes in anthropometric and thyroid hormone 
homeostasis parameters during the 12-month weight loss intervention. 
During the weight loss intervention (Panels A and B) a significant decrease 
in serum T3 was observed (Panel C). A trend toward a reduction in TSH 
and fT4 was also observed (Panels D and E). No significant difference was 
observed in the rT3 serum levels throughout the study. Repeated measure 
ANOVA, data are reported as mean±SEM.
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The submuscular transaxillary breast 
augmentation (TBA) is an established 
and preferred procedure for breast 
augmentation due to the limited visi-
bility of scar tissue, efficient sculpting 
of the implant pocket, and low rate of 
complication1. The objective of this 
study is to compare the complica-
tion rates of a nonendoscopic TBA 
approach to an endoscopic approach 
and to assess patient satisfaction 
with nonendoscopic TBA. A series 
of 353 TBAs were performed with 
saline implants and followed up by 
the senior author over a course of 
eight years, each at the same Level 1 
trauma hospital with the same group 
of anesthesiologists under either 
Low-grade gliomas are the most 
common brain tumor in children, and 
when they occur in the anterior visual 
pathway are called optic pathway 
gliomas (OPGs). Accurate and reli-
able vision testing in young children 
with OPGs can be limited by their 
cooperation. However, since not all 
OPGs cause vision loss, a surrogate 
marker of visual pathway integrity 
that does not require cooperation 
would be helpful.  
Spectral-domain optical coher-
ence tomography (SD-OCT), the 
Retinal Ganglion Cell Layer Thickness in Children  
with Vision Loss from Optic Pathway Gliomas
Sherry Gu, MSIII 
ADVISORS:  
Natalie C. Glaug, 
B.A.4, Roger J. 
Packer, M.D.1,2,3, and 
Robert A. Avery, D.O., 
M.S.C.E.1,2,3 
 
The George Washington University School 
of Medicine and Health Sciences (SMHS) 
1Department of Neurology, and 2SMHS 
Department of Pediatrics, and 3Gilbert Family 
Neurofibromatosis Institute, Children’s 
National Health System, Washington, D.C.
optical analog of ultrasound imaging, 
has emerged as a relatively noninva-
sive and time-efficient way to image 
the retina. When the visual pathway 
is damaged distally, the thickness 
of the unmyelinated retina will 
decreased due to axonal degenera-
tion. SD-OCT has proven to allow 
for safe, quantitative measuring 
of important retinal layers such as 
the ganglion cell layer-inner plexi-
form layer (GCL-IPL). We explored 
whether structural measures of the 
macular GCL-IPL using SD-OCT 
were related to visual acuity (VA) 
and visual field (VF) in children with 
OPG. 
Children with OPGs (sporadic or 
secondary to Neurofibromatosis type 
1, NF1) enrolled in a prospective study 
of SD-OCT were analyzed. Enrolled 
subjects were included only if macular 
SD-OCT images were acquired and 
they were cooperative for VA and VF 
testing. Manual segmentation of the 
macular GCL-IPL was performed 
across an Early Treatment Diabetic 
Retinopathy (ETDRS) grid at 1.5, 
3.0 and 4.5mm diameter. GCL-IPL 
thickness measures (microns) were 
compared to VA and VF outcomes.  
Forty-seven study eyes from 26 
children with OPGs (18 NF1-related, 
8 sporadic) were included, with a 
median subject-age of 5.3 years (range, 
2.5 – 12.8). The GCL-IPL thickness 
(3.0mm diameter) was decreased in 
the abnormal VA (61 ± 2 microns), 
abnormal VF (73 ± 11 microns) and 
abnormal VA/VF (53 ± 5 microns) 
groups when compared to the normal 
VA/VF group (92 ± 9 microns; F = 
44.9, p < 0.001).  GCL-IPL thick-
ness in the abnormal VA group was 
not different from the abnormal 
VF (Post-hoc Scheffe’s test, p = .28) 
and abnormal VA/VF groups (p = 
0.67), however the abnormal VA/VF 
group had a lower GCL-IPL than the 
abnormal VF group (p < 0.01). 
Children with vision loss (VA, 
VF, or both) from their OPG have 
decreased ganglion cell later-inner 
plexiform layer (GCL-IPL) thick-
ness compared to those children with 
normal vision. GCL-IPL thickness 
could be used as a surrogate marker 
of vision in children with OPGs.
Safety and Efficacy in Nonendoscopic  
Transaxillary Breast Augmentation:
A Safe and Cost-Effective Procedure that Maximizes 
Satisfaction and Minimizes Complications
Robert John 
Hagenberg, 
CPA, MSIII  
ADVISOR:  
George J. Bitar, 
M.D., FACS 
 
Bitar Cosmetic Surgery Institute
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Endoscopic Assistance? No Yes Yes Yes Yes Yes No No No
Total Number of Implants 353 47 58 197 160 359 331 1,682 344
Major Complications
Number of  
Complications
%of Total  
Patients
% of Total Implants
Capsular Contracture (Baker III/IV) 8 2.27% 2.13% 1.72% 0% 6.88% 1.39% 4.23% 1.90%
Ripling 2 0.57% 0.54%
Hematoma 1 0.28% 1.72% 0% 2.50% 0.28% 0% 0.12%
Mastitis 0 0.00% 0% 0% 0.06%
Sponaneous Implant Rupture 4 1.13% 1.72% 2.03% 1.11% 2,72% 3,57%
Implant Extrusion 2 0.57% 0.85%
High-Riding Implants (No Resurgery) 2 0.57% 0%
High-Riding Implants (with Resurgery) 2 0.57% 2.54%
Total High-Riding Implants 4 1.13% 6.38% 2.54% 0.28% 1.81% 1.70%
Breast Asymmetry 2 0.57% 1.52% 1.11% 3,32% 1,70%
Low-Riding Implants 1 0.28% 1.02% 0.58%
Total Malaligned Implants 7 1.98% 6.38% 1.72% 5.08% 1.39% 5.14% 2.97% 3.98%
Hypertrophic Scar 6 1.70% 2.03%
Cellulitis 0 0.00% 0.00% 0% 0%
Decreased Nipple Sensation 1 0.28% 1.02%











Total 35 9.92% 10.81% 6.90% 11.17% 9.38% 4.74% 13.90% 9.22% 11.00%
TABLE 1: This study’s breakdown of complication rates and side-by-side comarison with other TBA studies. 
general or laryngeal mask anesthesia 
(LMA). A retrospective chart review 
was conducted to ascertain compli-
cation rates and a literature review 
was performed to compare the rate 
of complication of endoscopic to 
nonendoscopic TBAs. Additionally, 
satisfaction surveys were sent to the 
353 nonendoscopic TBA patients 
via mail, email, and phone. The 
total complication rate, including a 
range of minor complications such 
as superficial infection to major 
complications such as hematoma 
requiring implant removal, was 9.92% 
(95% CI- 7.22-13.48%). See Table 1 
for a detailed breakdown and com-
parison between this nonendoscopic 
approach and literate detailing risk 
profiles of an endoscopic approach 
to TBAs. The complication rates of 
this non-endoscopic procedure are 
similar to the complication rates of a 
review of endoscopically guided TBA 
literature. Of the 353 patients, satis-
faction rates were received from 186 
or 52.69%. Of those who responded, 
the breakdown of satisfaction survey 
received by medium includes 32.8% 
by email, 19.4% by standard mail, and 
47.8% by phone. Level of satisfaction 
was measured on a 1–5 scale, 1 being 
poor and 5 being excellent, patients 
rated their nonendoscopic breast 
augmentations a mean of 4.46 (st. 
dev. 0.85) with a mean follow up time 
 SAFETY AND EFFICACY  
Continued on p. 10
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of 131.43 weeks (st. dev. 75.72) with a 
range from 1 to 470 weeks.  Due to 
a high patient satisfaction rate and 
comparable complication rates, the 
non-endoscopic approach to trans-
axillary breast augmentation is a safe, 
elegant, cost effective, and reputable 
procedure maximizing satisfaction 
and minimizing complications.
Although musculoskeletal com-
plaints have long been associated 
with spine pain, a limited number 
of investigations have sought to 
correlate tender points and trigger 
points with spinal pathology. A 
tender point, typically a hallmark of 
myofascial pain syndrome, is a point 
within a muscle that is painful upon 
local palpation. A trigger point, typi-
cally a hallmark of fibromyalgia, is a 
point within a muscle that produces 
radiating pain upon palpation 2. 
Cyriax suggests that tender points 
may be referred from cervico-tho-
racic, lumbro-sacral, and/or neural 
structures1. The current study was 
designed to determine whether 
pain perceived at the tender points 
or trigger points of several specific 
muscles of either the upper limb or 
the lower limb correlates to the site 
of injury, lesion, or pathology in the 
spine. A better understanding of 
pain referring to tender and trigger 
points from spinal and/or neural 
structures may allow for more effec-
tive therapies directed at the source 
of the pain, the spinal pathology, 
as opposed to the tender or trigger 
points themselves.
Fol lowing IRB approval, we 
performed a prospective, observa-
tional study of 50 subjects presenting 
with cervico-thoracic or lumbro-
sacral spine pain that may or may 
not radiate to the upper and lower 
extremities respectively. Excluded 
patients included those with a BMI 
greater than 30, a history of prior 
neck or back surgery, receiving or 
applying for disability compensation, 
undergoing litigation related to the 
injury, or the history of an epidural 
steroid injection within the last 
three months.  Algometry was used 
to measure the minimum pressure at 
which the patient begins to feel dis-
comfort, as opposed to maximal pain 
threshold. The algometer measures 
the pain pressure threshold at each 
muscle site in kg/cm2, with a stop-
ping point of 4 kg/cm2 (roughly the 
pressure required to cause an exam-
iner’s nail to blanch while testing 
these points manually), as is done per 
the standard of care.3 If the patient 
feels local pain only upon algometer 
application, he is said to have a tender 
point in that given muscle. If the 
patient feels radiating pain, he is said 
to have a trigger point. If the patient 
does not experience pain before the 
algometer reads 4 kg/cm2 of force, 
it is deduced that the patient has 
neither a tender nor a trigger point in 
that muscle. Algometery was used to 
obtain pain-pressure threshold mea-
surements of 10 muscles of the upper 
extremity and neck and 6 muscles of 
the lower extremity. 
Of patients with cervico-thoracic 
pain, 61% were found to have tender 
The Prevalence of Myofascial Tender and Trigger 
Points in Patients Presenting with Cervico-Thoracic  
and Lumbro-Sacral Spine Related Pain
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points and/or trigger points in spe-
cific muscles. Patients with lesions 
in C3-C4 presented more commonly 
with both tender points and trigger 
points located in the deltoid, trape-
zius, pectoralis major and triceps 
brachii; C5-C6 lesions with tender 
points in the latissimus dorsi, pec-
torlais major, and triceps brachii; 
C5-C6 lesions with trigger points in 
the deltoid, biceps brachii, and pec-
toralis major; and C6-C7 lesions with 
tender points in the pectoralis major, 
latissimus dorsi triceps brachii, and 
biceps brachii. Of patients with 
lumbro-sacral pain, 58% were found 
to have tender points and/or trigger 
points in specific muscles. Patients 
with lesions in L4-L5 presented more 
commonly with tender points located 
in the vastus medialis, adductor 
longus, and gluteus maximus; L4-L5 
lesions with trigger points in the 
gluteus maximus; L5-S1 lesions with 
tender points in the vastus medialis, 
tibialis anterior, and gluteus max-
imus; and L5-S1 lesions with trigger 
points in the gluteus maximus. The 
majority of diagnoses included spon-
dylosis, degenerative disc disease, 
disc bulging, and spinal stenosis. 
These preliminary results sug-
gest that tender and trigger points of 
selected upper and lower extremity 
muscles are correlated to spinal 
pathology. Therefore, therapy should 
be targeted at the corresponding 
spinal lesion. We expect to enroll a 
minimum of 100 subjects in this trial.
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Resistive Index (RI) calculated by 
Spectral Doppler ultrasound of the 
testis is a safe, non-invasive indicator 
of the intratesticular microcircula-
tion. The current body of literature 
has shown that RI is related to sper-
matogenesis, with an elevated RI 
indicating dyspermia. However, the 
literature does not specify locations 
in the testis where the RI is best 
measured. It is the goal of this study 
to evaluate measurement of RI from 
multiple areas in the testes to deter-
mine if significant differences exist.
A retrospective review of all tes-
ticular ultrasounds performed at our 
clinic from September 2011 through 
August 2012 yielded 214 patients 
Where Should Intratesticular Resistive Index Be 
Measured?
and 418 testicles (10 patients with 
solitary testis). Spectral Doppler 
interrogation of a single centripetal 
or recurrent rami artery from the 
upper, middle and lower portions of 
each testis was performed using a BK 
medical Flex focus ultrasound with 
an 18 mHz linear array transducer by 
a single sonographer. 
The average RI for the right and 
left was 0.56. When comparing the 
right and left testis there was no sta-
tistical difference (p-value of 0.86). 
In the right testis, there was no sta-
tistical difference when comparing 
the upper and lower values (average 
RI 0.56 and 0.56, respectively) to 
the mid-testis (average RI 0.56) with 
p-value of 0.68 and 0.79, respectively. 
There was also no statistical differ-
ence when comparing the right upper 
to the right lower testis, with p-value 
of 0.48. In the left testis, there was 
no statistical difference when com-
paring the upper and lower values 
(average RI 0.56 and 0.57, respec-
tively) to the mid-testis (average RI 
0.56) with p-value of 0.95 and 0.70, 
respectively. There was also no sta-
tistical difference when comparing 
the left upper to the left lower testis 
with p-value of 0.73.
Spectral Doppler ultrasound is 
a safe, non-invasive technique that 
adds unique real-time information 
about the intratesticular microvas-
culature and testicular function. This 
study found that the RI measure-
ments are not statistically different 
when measured from the upper, mid, 
or lower testis. Therefore, as the use 
of RI as an assessment of testicular 
function increases, this work sug-
gests that measurement of the RI can 
be taken from any area in the testis 
with equivalent results. The process 
of identifying an intratesticular 
artery and calculating the RI in the 
upper, middle, and lower pole of each 
testis can be time consuming. The 
ability to use a single measurement 
of RI from anywhere in the testis 
might encourage urologists to obtain 
this measurement as an independent 
marker of testicular function.
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Children with congenital heart dis-
ease often require surgical procedures 
at a young age. Thromboembolic 
complications (TC) are a major 
source of post-operative morbidity 
and mortality in children undergoing 
cardiac surgery with cardiopulmo-
nary bypass (CPB). Thrombosis pro-
ceeding pediatric cardiac surgery are 
associated with platelet dysfunction, 
blood hypercoagulability, inflamma-
tion, and disruption of blood flow. In 
addition, patients’ immature coagu-
lation system results in character-
istically low capacity to inhibit clot 
formation and elevated resistance to 
anticoagulants.1, 2, 3
Data on thrombosis associ-
ated with pediatric cardiac surgery 
are limited and hence association 
Association Between Thromboembolic  
Complications and Increased Mortality After  
Pediatric Cardiac Surgery
between TCs and surgical outcomes 
in this population is not well under-
stood. In a retrospective study, 1,542 
pediatric cardiac surgeries performed 
from September 2004 to December 
2007 were quantified and charac-
terized for post-operative TCs and 
surgical risk factors respectively. 
Ten percent of the patients (152/1,542) 
were identified to have TCs. Of those 
patients, in-hospital mortality for all 
causes was 15% (23/152), while TCs 
served as a primary or a secondary 
cause in 12/23 (52%) of all deaths. In 
addition, isolated intracardiac TCs 
or TCs in multiple vascular systems 
were associated with more than 
double the risk for cardiac arrest 
(P=0.04) and mortality (p=0.009) 
relative to patients with isolated 
intra-venous or intra-arterial TCs. 
These findings suggest that TCs after 
cardiac surgery are significantly asso-
ciated with poor clinical outcomes 
and occur at a higher rate compared 
to the overall cases of thrombosis in 
the pediatric population. 
To further investigate this matter, 
a large-scale cross-sectional study 
is currently in progress. This study 
includes experimental laboratory 
investigations, diagnostic protocols, 
and long-term patient follow-up. This 
would serve to strengthen previous 
findings and help further enhance 
the current understanding of TCs 
with respect to quantification, char-
acterization, and risk stratification. 
The goal is to permit the develop-
ment of effective tools necessary for 
prevention and early identification 
of TCs instead of treatment alone. 
Accordingly, clinicians can identify 
patients that may require more 
aggressive thromboprophylaxis, 
enhance assessment post-operatively, 
and implement more aggressive treat-
ment strategies.
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CLINICAL 11
Exercise plays a major role in the 
prevention and management of Type 
2 Diabetes (T2D) by increasing the 
rate at which skeletal muscle cells 
take up glucose. A number of clinical 
trials have illustrated that moderate 
physical activity and proper diet can 
decrease the progression of impaired 
glucose tolerance as seen in T2D1,3. 
Individuals with T2D participating 
in exercise interventions greater 
than eight weeks duration had sig-
nificantly lower HbA1c levels than 
the individuals who did not exercise 
— highlighting the importance of 
regular exercise for T2D patients2. 
Recent genetic studies examining 
T2D have implicated genes involved 
in several potential therapeutic path-
ways involving those associated with 
β-cell dysfunction, insulin packaging 
and secretion. One variant, highly 
associated with T2D, was a non-
synonymous change in the SLC30A8 
gene that encodes for the Zinc 
Efflux Transporter 8 protein (ZnT-8) 
expressed mainly in the β-cells of the 
pancreas — responsible for storing 
and releasing insulin. The variant 
in SLC30A8 (rs13266634) gives rise 
to a Tryptophan at amino acid 325 
in place of an Arginine, resulting 
in a defective ZnT-8 protein. In the 
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absence of a properly functioning 
ZnT in vesicles, insulin cannot be 
synthesized and stored appropri-
ately, disrupting glucose uptake 
and Adenosine triphosphate (ATP) 
formation downstream. The pri-
mary objective of our study was to 
determine whether there is a link 
between exercise capacity and the 
SLC30A8 (rs13266634) variant gene. 
We hypothesized that this variant in 
the SLC30A8 gene may help explain 
differences in muscle response to 
exercise, possibly due to insufficiency 
in glucose uptake and ATP synthesis. 
 Two cohorts with a total of 697 
participants were subjected to one 
of two interventions to determine 
SLC30A8 GENE Continued on p. 14
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the effects of exercise on muscle. 
Our results indicated that rs13266634 
variant is strongly associated with 
several different muscle phenotypes 
in men but not in women. Male 
carriers of the common allele were 
more likely to demonstrate greater 
post-workout strength loss and 
greater perceived soreness (Figure 1). 
Increased markers of muscle damage 
— creatine kinase (Figure 2) and myo-
globin (Figure 3) — were also strongly 
associated with the common allele. 
Furthermore, affected heterozygotes 
(CT) and homozygotes (CC) were 
more likely to have decreased base-
line whole muscle volume (Figure 4) 
and decreased baseline 1-repetition 
maximum strength (Figure 5).
 In this era of increasing interest 
in personalized medicine, there is 
an intense search for genetic markers 
that can be used in preventing and 
managing T2D. Clinically, the out-
come of our study may help iden-
tify patients for whom resistance-
training is an optimal f irst-line 
therapy in the management and 
treatment of T2D. We have demon-
strated that the rs13266634 variant in 
SLC30A8 may be used as an indicator 
for those individuals who may not 
respond to exercise as the first-line 
therapy for T2D, and may require 
an alternative method to manage 
their impaired glucose tolerance. 
Additional research is needed to 
determine if the presence of this 
single-nucleotide polymorphisms 
(SNP) and predisposition to post-
exercise soreness leads to a decreased 
desire to be active, thus, promoting 
a more sedentary lifestyle, further 
amplifying their risk of developing 
T2D. We are intrigued by the notion 
that this SNP might influence several 
facets of T2D progression.
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independence, including making 
their own nutritional choices1. Quality 
nutrition is strongly recommended 
to improve health (e.g. lower LDL 
plasma levels), and potentially offset 
risk factors for cardiovascular (CV) 
disease in individuals with T1D2. Our 
objective was to evaluate the rates of 
adherence to nutritional guidelines in 
youths with T1D and to examine the 
association of nutritional quality and 
Hemoglobin A1c (HbA1c). 
Baseline data from a randomized 
controlled trial of an intervention 
designed to prevent deterioration of 
glycemic control in young adolescents 
with T1D were evaluated. Adolescent-
parent dyads (n = 257, youth mean age = 
12 years, SD = 1.2 years, 49.4% female, 
64% intensive insulin regimen, mean 
HbA1c = 8.8, SD = 1.6) reported dietary 
intake via two 24-hour recall inter-
views as a component of their diabetes 
self-care. Participants were stratified 
by insulin regimen. Participants who 
reported four or more injections or 
use of an insulin pump were consid-
ered intensive. Conventional therapy 
involved a more structured insulin 
regimen including a set amount of 
carbohydrates and insulin intake per 
meal and fewer injections. Intensive 
therapy offered greater f lexibility 
with calculating insulin needs, based 
on insulin to carbohydrate ratios, 
for each food consumed. Dietary 
NUTRITION Continued on p. 16
For youth with Type 1 Diabetes 
(T1D), adolescence is characterized 
by a period of poor adherence. One 
reason for poor adherence may be 
related to youth establishing their 
3.  Cuff DJ, Meneilly GS, Martin A, Ignasze-
wski A, Tildesley HD, Frohlich JJ. Effective 
Exercise Modality to Reduce Insulin Resis-
tance in Women With Type 2 Diabetes. 
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FIGURE 1: Participants Who Met Dietary Recommendations
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TABLE 1: Recommended Guidelines for Adolescents with Type 1 Diabetes 
Recommendation Reference
% calories from carbs 50–55% ISPAD
% calories from protein 15–20% ADA
% calories from fat 30–35% ISPAD
% saturated fat < 7% of total calories ADA
Polyunsaturated fat < 10% ISPAD
Monounsaturated fat 10–20% ISPAD
Cholesterol < 200mg/day ADA
Dietary Fiber 14g/1000kcal ADA,  
HP2010
BMI Overweight 85th–94th percentile (25.0–29.9 kg/m2) 
Obese ≥ 95th percentile (≥ 30kg/m2)
ADA
Blood Pressure 130/80 mmHg or 90th percentile for  
age, sex, and height
ADA
LDL cholesterol < 100mg/dL ADA
ISPAD = International Society for Adolescent and Pediatric Diabetes; ADA = American Diabetes 
Association; HP2010 = Healthy People: 2010
intake was scored using The Food 
Processor® Nutrition Analysis 
Software (ESHA Research, Salem, 
OR, USA). Demographic variables 
and HbA1c data were abstracted from 
questionnaires and medical charts. 
When compared to the American 
Diabetes Association (ADA) and 
International Society for Pediatric 
Diabetes (ISPAD) recommendations, 
many youths were not meeting nutri-
tional guidelines. This included per-
cent daily intake of protein, carbohy-
drates, fat, saturated fat, cholesterol, 
and dietary fiber. Furthermore, 50.2% 
of participants reported LDL choles-
terol levels greater than recommended 
guidelines for primary prevention 
of CV disease in youths with T1D3. 
Significant positive correlations were 
found between HbA1c and percent of 
total calories from fat (r = .24, p < 0.01), 
polyunsaturated fat (r = .16, p < 0.05), 
dietary cholesterol (r = .20, p < 0.01), 
and LDL (r = .24, p < .01).  Significant 
negative correlations were identified 
between HbA1c and percent of total 
calories from carbohydrates (r = -.23, 
p < 0.01) and dietary fiber (r = -.13, p 
< 0.05). 
The majority of early adolescents 
with T1D did not meet nutrition 
guidelines. This may place them at 
increased risk for CV diabetes-related 
complications, which was suggested by 
increased LDL plasma levels reported 
in this adolescent study population. 
Further, several indices of nutrition 
were associated with glycemic control, 
NUTRITION Continued from p. 15
suggesting that there may also be a 
short-term impact linked to failure 
to adhere to nutritional guidelines. 
In addition to monitoring blood 
glucose levels, HbA1c has utility as a 
risk factor for CV disease. Our study 
supports a link between nutritional 
intake, HbA1c, and risk factors for 
CV disease. Diabetes education 
efforts regarding healthy eating and 
dietary management may need to be 
enhanced to achieve recommenda-
tions and ultimately improve health 
outcomes for those with T1D.
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CLINICAL 15
Venous thromboembolism (VTE) 
is a serious, potentially deadly, post-
operative morbidity that occurs in 
up to 34.6% of gynecologic oncology 
patients who do not receive antico-
agulant prophylaxis1. VTE refers to 
both deep vein thrombosis (DVT) and 
pulmonary embolism (PE). A DVT is 
a blood clot in a deep vein, typically 
originating in the leg, which runs the 
risk of dislodging and traveling in the 
bloodstream up to the lungs at which 
point it can become a life threatening 
PE. Roughly 200,000 deaths each 
year are caused by PEs and non-fatal 
instances of VTE result in prolonged 
hospitalization and outpatient care. 
While the American College of 
Chest Physicians (ACCP) recom-
mends anticoagulant prophylaxis in 
the general surgical oncology popula-
tion, no specific recommendations 
are available in regards to how long to 
extend prophylaxis for patients within 
this patient population2. AACP guide-
lines for these patients are based upon 
studies with small sample sizes and 
they tend to group all gynecologic 
oncology patients into one cohort.
We hypothesized that the timing 
of perioperative prophylaxis, patient 
age and BMI, tumor type and his-
tology, and mode of surgery (laparos-
copy versus laparotomy) are impor-
tant risk factors in this gynecologic 
oncology patient population. To 
Patterns of Post-Operative Venous Thromboembolism 
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investigate this, we performed a ret-
rospective cohort study of 527 gyne-
cologic oncology patients who under-
went surgery from 2008 through 2011 
at a major academic institution. Prior 
to Jan. 1, 2010, gynecologic oncology 
patients were given post-operative 
subcutaneous heparin three times 
daily, total ionizing dose (TID), and 
they wore sequential compression 
stockings. Starting Jan. 1, 2010, in 
addition to the post-
operative hepa r i n 
TID and sequential 
compression stock-
ings, oncology patients 
u ndergoi n g m ajor 
gynecologic surgery 
were given a preop-
erative dose of heparin 
and two weeks of post-
operative low molec-
ular weight heparin 
after discharge.
Of our cohort of 527 patients, 28 
occurrences of VTE were noted (11 
DVT and 17 PE). In comparison to 
patients with no incidence of VTE, 
patients with VTE were older (mean 
age 64 vs. 54, p < 0.001) and had a 
higher BMI (32 vs. 29, p=0.048). 
We found that malignancy, blood 
transfusion, surgical tumor deb-
ulking, and wound infection were all 
significantly associated with VTE 
(p<0.001). Features of malignancy, in 
particular tumor grade and histology, 
were found to be statistically signifi-
cant. We noted a VTE incidence of 
15.1% in patients with grade three 
tumors in comparison to only 1.7% 
incidence in those with grade one or 
grade two tumors (RR 8.66, p<0.001). 
We hypothesized that three tumor 
histologies — clear cell, serous, and 
malignant mixed Mullerian tumor 
(MMMT) — put patients at a greater 
risk for developing a VTE. In a mul-
tivariate analysis, these three tumor 
histologies were 7.4 times more likely 
to be associated with a VTE event 
compared to all other histologies in 
our study (p<0.001).
As previously mentioned, the 
ACCP guidelines offer prophylaxis 
guidelines that apply to the entire 
gynecologic oncology patient popula-
tion. We found that patient age, BMI, 
tumor grade and histology, as well as 
the nature of surgical intervention, 
were relevant risk factors for the 
occurrence of VTE. Our study sug-
gests that further research on risk fac-
tors for VTE within the gynecologic 
patient population is warranted, as 
it may inform future clinical guide-
lines that would enable physicians to 
tailor the extension of anticoagulant 
prophylaxis based upon individual 
patient need. Current validation of 
a clinical prediction rule for gyneco-
logic oncology surgery is underway.
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Roughly 200,000 deaths each year 
are caused by PEs and non-fatal 
instances of VTE result in prolonged 
hospitalization and outpatient care. 
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Care provided in the Emergency 
Department (ED) is often the first 
and only treatment for many people, 
and prior research has shown that 
the ED is used frequently by persons 
with mental health conditions1, 2. In 
2007, 12.5% of the 95 million ED 
visits were attributed to mental 
health and/or substance abuse3. 
ED physicians increasingly come 
into contact with patients suffering 
from issues such as major depressive 
disorder (MDD). The American 
Psychiatric Association4 defines 
MDD as a period, lasting at least two 
weeks, where the person has either 
depressed mood or a loss of interest 
in pleasure, disturbances in sleep, 
disturbances in appetite, low energy, 
lack of concentration, psychomotor 
retardation or agitation, guilt, and/
or suicidal ideation. This study mea-
sured resident ED physician comfort 
Emergency Department Physicians’ Comfort Levels 
with Diagnosing and Treating Depression
levels working with this popula-
tion by assessing the ED residents’ 
attitudes toward diagnosing and 
treating patients who come to the 
ED with depression as compared to 
two other common disorders that the 
residents encounter — diabetes and 
hypertension.
Participants were asked how 
comfortable they were making a new 
diagnosis of hypertension, diabetes 
mellitus (DM), and MDD using 
a 5 point Likert scale in which “1” 
represented strongly disagree and 
“5” represented strongly agree. We 
also examined comfort levels with 
prescribing medications for MDD 
compared to hypertension and dia-
betes in three scenarios. The first 
without follow-up (no primary care 
provider (PCP); the second with 
a PCP available for follow-up but 
without speaking to him/her; and 
the third with an available PCP that 
is reachable by phone. We also exam-
ined perceived barriers to initiating 
treatment for MDD in the survey.
Twenty residents in GW’s School 
of Medicine and Health Sciences 
Department of Emergency Medicine 
responded to the survey. They exhib-
ited significantly lower levels of com-
fort making an initial diagnosis of 
MDD 2.45 (95% CI 2.03, 2.87) when 
compared to either hypertension 3.90 
(95% CI 3.28,4.52) or diabetes 4.00 
(95% CI 3.52, 4.48).  Residents were 
less comfortable prescribing medica-
tion for depression as compared to 
hypertension or diabetes across all 
scenarios. The most common barrier 
to treatment was lack of comfort with 
treating patients without follow-up.
Residents have a low level of com-
fort in treating MDD as compared 
to conditions such as hypertension 
and diabetes. Further research is 
needed to examine residents’ atti-
tudes toward diagnosing and treating 
depression, and its perceived barriers. 
Limitations of the study include the 
small sample size. Our study sug-
gests that ED residents may benefit 
from additional training in diagnosis 
and treating MDD. Due to the high 
number of MDD patients who use 
ED services, resident curriculums 
may benefit by promoting a stronger 
emphasis on MDD diagnosis and 
treatment.    
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Airway epithelium is recognized as 
a key tissue in studying lung diseases 
based on its role as a polarized, dif-
ferentiated barrier.1 It simultaneously 
responds to airborne pathogens and 
environmental challenges at the 
apical surface while creating local 
and systemic changes based on these 
external stimuli.2 Proteins secreted 
apically and basally by epithelial 
cells are likely to be part of a critical 
signaling network between airway 
environment and systemic milieu. 
Alterations in the airway epithelial 
barrier may lead to dysregulated sig-
naling and subsequent clinical symp-
toms observed in many lung diseases 
such as: asthma, bronchitis, and cystic 
fibrosis. In asthma, previous studies 
have demonstrated that allergen 
challenge tests result in upregulation 
of many proteins associated with 
inflammation, eosinophilia, airway 
remodeling, tissue damage, and 
mucus production relative to non-
asthmatics.3 These studies on ex vivo 
airway samples suggest that through 
the application of proteomic tech-
niques, such as Western Blot, ELISA, 
and flow cytometry to in vitro models, 
may provide a unique opportunity 
for global understanding of protein 
interactions for a given disease state 
and mechanisms.4
Our recent data demonstrated 
that bronchial epithelium in treated 
asthmatics have only basolateral 
increases of specific cytokines com-
pared to non-asthmatics, which 
have both apical and basolateral 
seceretions.5 To our knowledge, no 
study has characterized the apical 
and basolateral secretomes of airway 
epithelium. Defining these secre-
tomes in normal in vitro Human 
Bronchial Epithelial (HBE) models 
would lay the foundation for future 
comparative studies in disease. Our 
bioinformatic analysis of significant 
proteins identified in both apical and 
basolateral secretions detected sev-
eral biological processes that appear 
homeostatic in nature with subtle, 
yet significant, differences in the 
distribution of these process between 
apical and basolateral secreted pro-
teins (see Table). Our results revealed 
that certain proteins were secreted 
only into the apical or basolateral 
TABLE: Differentially Expressed Proteins in Apical vs Basolateral Compartments
Uniprot ID Protein* Location† P Value‡ Fold Change§
(Apical/Basal)
Q16787 Laminin subunit alpha-3 Secreted 0.032 -12.71
O75635 Serpin B7 Cytoplasm 0.048 -3.17




P35241 Radixin Exosome 0.035 2.77
P60709 Actin, cytoplasmic 1 Cytoplasm 0.002 2.91
P63261 Actin, cytoplasmic 2 Cytoplasm 0.002 2.91
P68133 Actin, alpha skeletal muscle Cytoplasm 0.042 3.08
P15311 Ezrin Exosome 0.003 4.87
P28070 Proteasome subunit beta type-4 Cytoplasm 0.037 5.23
P27348 14-3-3 protein theta Cytoplasm 0.019 5.99
P20618 Proteasome subunit beta type-1 Cytoplasm 0.036 6.25
Q04917 14-3-3 protein eta Unknown 0.039 6.73
P02768 Serum albumin Secreted 0.036 11.20
*  Identified in all apical and basolateral secretions with differential expression based on Student T-test.
†  Location based on Uniprot and SignalP databases; exosome distinction based on previous study(16) 
‡  Based on two tailed Paired Student T-test; only proteins with p<0.05 are listed.
§  Based on average normalized spectral count calculated in ProteoIQ. Positive value denotes increased 
expression in apical secretions; negative value denotes increased expression in basolateral 
secretions.
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compartments of the tissues and 
others were differentially secreted 
between these two compartments. 
All samples tested demonstrated 
through proteomic evaluation, that 
the epithelial layer directionally 
expresses proteins and that the pur-
pose of this is functional in nature.
In this study we successfully char-
acterized directional in vitro normal 
airway secretomes through compre-
hensive evaluation of apical and baso-
lateral secreted proteins. Specifically, 
we identified the normal apical and 
basolateral secretomes in the gold 
standard model for studying mecha-
nisms of airway diseases — in vitro 
DIRECTIONAL SECRETOMES 
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primary differentiated bronchial 
epithelium. We identified intrinsic 
proteins uniquely expressed in both 
compartments and differentially 
expressed between compartments 
in cell cultures from multiple donors. 
Future validation of this in vitro 
secretome model in ex vivo specimens 
will enhance our understanding of 
lung diseases. In addition, by estab-
lishing a model to test ex vivo tissue 
in in vitro technique, we have high-
lighted potential therapeutic markers 
that can be used in future airway 
secretome studies to allow for a more 
efficient and practical path towards 
personalization of medical care.
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Human herpesviruses (HHV) are 
characterized by their unique ability 
to productively infect or remain 
latent in the host cell. The ini-
tiation of lytic replication can be 
induced by external or internal 
stimuli, such as cytokines or che-
mokines. Chemical agents such as 
tetradecanoylphorbol-13 –acetate 
(TPA), which stimulate cell signal 
transduction pathways, can also 
induce viral replication.1 For Kaposi’s 
Sarcoma-associated Herpesvirus 
(KSHV or HHV-8), the viral pro-
tein that was thought to trigger 
the cascade of events leading to 
lytic replication was the replication 
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and transcription activator protein 
(RTA).2 In an initial attempt to char-
acterize genes expressed while RTA 
was inactivated, an unexpected event 
was observed, in which agents that 
induce apoptosis appeared to trigger 
KSHV replication suggesting that 
an alternative replication program 
induced by host cell apoptosis can 
initiate KSHV replication in the 
absence of RTA.3
The question is whether this 
alternative replication program is 
unique to KSHV or if it is a common 
feature of all herpesviruses. In par-
ticular, we focused our efforts on 
HHV-4 (also known as Epstein Barr 
Virus or EBV), HHV-6B, HHV-6A 
and HHV-7. If apoptosis appears to 
induce replication we can conclude 
this may be a common feature of the 
herpesvirus. 
Here we show that 2[[3-(2,3-dichlo-
rophenoxy)propyl]amino] ethanol 
(DCPE), induces apoptosis in cell 
lines latently infected with EBV, 
HH V-7, HH V- 6B, and - 6A by 
staining cells with annexin V and 
propidium iodide (PI) and measured 
using f low cytometry. Annexin V 
targets a protein, phosphatidyl-
serine, expressed on the surface of 
cells undergoing early apoptosis. 
Propidum iodide binds to DNA and 
cannot permeate viable cell mem-
brane so effectively detects cells in 
late apoptosis. Results for EBV and 
HHV-7 are shown in Figure 1. The 
known viral replication-inducing 
agent TPA was used as a positive 
induction control for normal viral 
replication. Cells latently infected 
with KSHV were also used as a 
positive control, since the alterna-
tive apoptosis-induced replication 
pathway for this virus has already 
been shown to exist. 
We showed t hat apoptotic 
inducing agent, DCPE, induces 
viral replication in EBV and HHV-7 
latently infected cel ls l ines by 
RT-PCR assays for vira l DNA. 
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There was a significant increase in 
the amount of viral DNA in EBV 
and HHV-7 latently infected cell 
lines as compared to the untreated 
cells when treated with either TPA 
or with apoptotic inducing agent, 
DCPE (Figure 2). We were not able 
to quantify viral DNA in HHV-6A 
and -6B latently infected cells likely 
due to the primers that were used. 
Additional experiments to quantify 
the viral DNAs are in progress.
Lastly, we demonstrated viral pro-
tein expression induced by apoptosis 
occurs for KSHV, HHV-4, HHV-
6B, and HHV-7 latently infected 
cell lines by targeting virus-specific 
proteins with primary and secondary 
antibodies that were then visualized 
by confocal microscopy.
Overall, our data suggests that 
an alternative apoptosis-triggered 
replication program appears to be a 
general feature of the herpesvirus. 
The presence of an alternative rep-
lication pathway shown in EBV and 
HHV-7 latently infected cell lines is 
not surprising due to their close taxo-
nomical relationship with KSHV, 
as well as the evolutionary benefit 
an apoptosis-induced alternative 
replication pathway would provide. 
Cytotoxic therapy is often required 
to treat neoplasms caused by these 
viruses including Kaposi’s sarcoma 
and Burkitt’s lymphoma caused 
by KSHV and EBV, respectively. 
Therefore, it may prove beneficial 
to treat neoplasms caused by these 
viruses with antiviral agents in addi-
tion to cytotoxic therapy.
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FIGURE 1: 2,3 DCPE induces apoptosis in cell lines latently infected 
with herpesvirus measured by flow cytometry. Latently infected cell 
lines were treated with TPA or 2,3 DCPE for 24hrs and then stained with 
annexin V and propidium iodide (PI) and measured by flow cytometry. 
A high percentage of cells treated with 2,3 DCPE showed annexin V and 
PI positivity.  Note: lower left quadrant represents % live cells (annexin 
V - and PI - ), lower right quadrant represents % cells in early apoptosis 
(annexin V + and PI - ),  upper left quadrant represents % cells in late 
apoptosis (annexin V - and PI +), and upper right quadrant represents 
% cells in early and late apoptosis (annexin V + and PI +).
FIGURE 2: Apoptosis (2,3 DCPE) Induces High Viral DNA Replication in 
KSHV, EBV and HHV-7 Latently Infected Cell Lines
20 Fusion  2014
Beta defensins are antimicrobial 
peptides that are part of the innate 
immune system and produced by the 
skin to combat skin infections.1 The 
skin of atopic dermatitis patients is 
deficient in these peptides, which may 
increase their susceptibility to recur-
rent skin infections. These infections 
occur due to the significant barrier 
disruption, chronic skin inflamma-
tion, and impaired innate immune 
response that are characteristic of the 
disease.2 Compounds that induce the 
production of beta defensins in the 
skin without concurrently inducing 
inflammatory cytokines have poten-
tial use in atopic dermatitis therapy 
The Search for Novel Atopic Dermatitis Therapies: 
β-Defensin-Inducing Plant Extracts
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and screening methods have been 
developed to screen plant extracts 
with this profile.3
Two such extracts, dubbed Extract 
A and Extract B, were identified that 
showed promise in this area. Each 
was tested on cultured keratinocytes 
from normal and atopic beagles to see 
if they induced the production of beta 
defensin (BD103), which is analogous 
to human beta defensin 3 (hBD3), 
without increasing inf lammatory 
mediators. This was accomplished by 
allowing the keratinocytes to reach 
confluence and remain in that state 
for two days. They were then starved 
overnight in starving media and 
placed in starving media containing 
the concentrations of the extracts for 
24 hours, along with positive (IL-1b 
100 ng/ml) and negative (Dulbecco’s 
Phosphate-Buffered Saline) con-
trols. The production of BD103 
was assessed following application 
of increasing concentrations of the 
extracts (0.2%, 0.4%, 1% for Extract 
A and 0.2%, 0.4%, 1%, 1.5%, 2% for 
Extract B) to the keratinocytes using 
quantitative real-time PCR, while 
two mediators of inflammation, IL-8 
and TNF-α, were assessed using 
ELISA.
 Analysis of the PCR and ELISA 
results was done through indepen-
dent paired t-testing on mean values 
to determine statistical significance 
(P < 0.05). Extract B at 2% showed 
a significant increase in TNF-α 
in atopic keratinocytes compared 
to baseline (negative control) and 
normal keratinocytes, while also 
showing a significant decrease in 
IL-8 in normal keratinocytes com-
pared to baseline. At 1.5%, Extract 
B showed a significant increase in 
BD103 in atopic keratinocytes com-
pared to baseline, while also showing 
a significant decrease in IL-8 in 
atopic keratinocytes compared to 
baseline. Extract A at 1% showed 
in both atopic and normal keratino-
cytes a significant increase in IL-8 
FIGURE 2: Extract B relative increase in beta-defensin 
103 mRNA to baseline
FIGURE 1: Extract A relative increase in beta-defensin 
103 mRNA to baseline
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compared to baseline, as well as at 
0.4% in atopic keratinocytes com-
pared to baseline. Extract A appeared 
to have the opposite effect to what 
is desired because it increased an 
inflammatory marker, IL-8, without 
increasing BD103 production.
The results from Extract B (1.5%) 
show that pursuing further testing 
on not only Extract B, but also other 
plant-based compounds that, through 
screening, show pro-beta defensin 
and anti-inflammatory properties, 
could be valid in the search for novel 
therapies and tools for the prevention 
of recurrent skin infections in atopic 
dermatitis patients. It is important 
to note that this is an ongoing study 
and as keratinocytes from more dogs 
are tested, statistical significance for 
different concentrations may change. 
As this study was in-vitro, the next 
step would be to test these extracts 
on live atopic dermatitis models in 
hopes of translating this potential 
medicine to humans as a way to pro-
tect this vulnerable population from 
skin infections. 
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Bladder outlet obstruction (BOO) is a 
pathological condition characterized 
by increased bladder pressure and 
decreased urine flow that may result 
in the complete loss of bladder func-
tion.1 Pathological symptoms may 
include abnormal thickening of the 
detrusor muscles and may ultimately 
result in the loss of bladder compli-
ance and filling efficiency. There are 
many causes of BOO, ranging from 
spina bifida to prostate overgrowth, 
making BOO a difficult condition 
to treat.1 
Currently, surgical correction 
remains the most effective treatment 
for BOO. However, replacement 
tissues used are often transplanted 
from the GI tract. This may result in 
systemic acidosis and carcinogenesis 
because acid secreting tissues were 
accidentally incorporated into the 
bladder. 
A potential alternative solution 
for this would be to use skin-derived 
precursor cells (SKPs). SKPs are 
easily accessible, pluripotent and 
cost-effective. In order to deter-
mine the specificity of SKP dif-
ferentiation, we performed PCR 
analysis, using smoothelin gene as a 
marker. There are two isoforms of 
smoothelin; A and B. Smoothelin A is 
expressed in bladder smooth muscle 
cells while smoothelin B is expressed 
mainly in vascular smooth muscle 
cells. Interestingly, when SKPS are 
cultured in conditioned media that 
is not subjected to stress, there is a 
high ratio of smoothelin A:B (Figure 
1). This suggests that SKPs have the 
potential to differentiate into bladder 
BLADDER OBSTRUCTION  
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FIGURE 1: Smoothelin isoform ratio of SKPs under different 
conditions
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smooth muscle cells in non-strained 
conditions, making them an ideal 
replacement tissue for BOO correc-
tive surgery in the future.
Pharmacological treatment may 
be another option for treating BOO. 
Sirolimus (rapamycin), an immune 
suppressant that showed remarkable 
efficacy in treating stent stenosis 
and other diseases characterized 
by abnormal muscle proliferations.2 
Current literature also suggests that 
both vascular and bladder smooth 
muscle cell proliferation requires 
the mTOR pathway. Sirolimus, 
an mTOR inhibitor, may be an 
effective agent in preventing the 
thickening of the bladder wall and 
the eventual development of BOO.
I n  or d er  to  s i mu l ate  t he 
obstructed bladder, rat bladder 
smooth muscle cells were subjected 
to hypoxia and stretch in vitro. As 
expected, this resulted in a hypertro-
phic response and the cells became 
thicker and much more numerous 
(Figure 2). Smooth muscle actin 
expression, a protein marker for the 
level of differentiation in bladder 
smooth muscles, also became signifi-
cantly down-regulated in response to 
both mechanical and hypoxic stress.
After sirolimus was added, the 
hypertrophic response elicited by 
hypoxia and stretch was prevented. 
Smooth muscle actin levels were 
also maintained at a high level in the 
sirolimus treated cells (Figure 2). This 
indicates that bladder smooth muscle 
cells maintained a differentiated and 
therefore functional state. This is 
important as much of the pathology 
associated with BOO is due to the 
improper contraction of the hyper-
trophic and de-differentiated bladder 
smooth muscle wall. Ultimately, 
Sirolimus administration may allow 
the bladder to continue to contract 
efficiently, even in the presence of 
BOO inducing stressors like injury, 
hypoxia and stretch. Consequently, 
further studies in human cells are 
needed for its potential to be fully 
used.
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Underdiagnosed Pain in HIV/AIDS Patients
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Human Immunodeficiency Virus 
(HIV) is primarily a sexually trans-
mitted disease that depresses the 
body ’s immune system — spe-
cif ically the depletion of CD4+ 
T-lymphocytes. Individuals with 
CD4+ counts of <200 cells/μL are 
defined as having Acquired Immune 
Deficiency Syndrome (AIDS). In the 
United States alone, there are approx-
imately 1.1 million individuals living 
with HIV/AIDS with an incidence 
of 56,000 new infections each year. 
Clinically, HIV/AIDS presents 
with myriad symptoms, including 
various cardiovascular diseases, 
hepatobiliary diseases, renal dis-
eases, or, most commonly, secondary 
opportunistic infections. These 
symptoms can often be controlled 
with highly active anti-retroviral 
therapy (HAART), which effectively 
produces a state of chronic-treated 
HIV/AIDS. Chronic persistence of 
the virus may involve the central ner-
vous system and lead to neurological 
symptoms such as cognitive impair-
ment, gait disorders and various pain 
syndromes1.
Though commonly occurring 
and despite the importance of pain 
management in chronic HIV, pain 
syndromes continue to be under-
recog n ized a nd u nder treated. 
Furthermore, clinicians seldom 
explore HIV-associated pain syn-
dromes2. The most common pain 
syndrome occurring in HIV/AIDS 
patients is distal sensory polyneu-
ropathy (DSP), which initially pres-
ents as paresthesias in the fingers and 
toes in a “stocking and glove distribu-
tion.” Weeks later, it converts into a 
burning and “knife-stabbing” pain3,4.
While the specific mechanisms of 
DSP are still uncertain, many studies 
have suggested that it is due to a com-
bination of the virus, CNS immune 
response, and specific treatments. 
The envelope protein of the virus 
(gp120), spinal cord glial cells (with 
their respective chemokine receptors 
CXCR4 and CXCR5) and nucleo-
side reverse transcriptase inhibitors 
(NRTIs) may all be implicated in the 
formation of DSP5. In brief, gp120 
can increase prostaglandin E2 levels 
and, through Kappa opioid pathways, 
facilitate an increase in intracellular 
calcium. This signals the mitochon-
drial to release reactive oxygen spe-
cies (ROS) and nitric oxide (NO) and, 
ultimately, leads to pain. Another 
possible mechanism is through direct 
or indirect (viral shedding in PNS) 
activation of glial cells at their respec-
tive chemokine receptors. Once acti-
vated, they release pro-inflammatory 
cytokines (TNFa, IL-1 and IL-6) that 
directly promote increased neuronal 
sensitivity to pain. NRTIs can exac-
erbate these effects by increasing the 
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as directly increasing intracellular 
calcium, leading to an enhanced pain 
state (Figure 1).
HIV-related DSP appears to 
be resistant to most first-line neu-
ropathic pain pharmacotherapy5. 
While many randomized controlled 
trials (RCTs) of pharmacological 
treatments for DSP have been per-
formed, few demonstrate superiority 
over the placebo. The most notable of 
the group is the clinically available 
high-dose topical capsaicin [NNT 
6.46, 95% CI (3.86-19.69)]. Another 
exception, although not recom-
mended as routine, is smoked can-
nabis [NNT 3.38, 95% CI(1.38-4.10)]. 
Recombinant human nerve growth 
factor (rhNGF) has shown promise 
in a recent study but is not clinically 
available6. Finally opioids, especially 
chronic mu-receptor agonists, can be 
used to treat DSP but some studies 
have cautioned that they should only 
be used on a short-term basis and only 
when there are no alternatives due to 
their potential pro-nociceptive prop-
erties in HIV-DSP patients5.
It needs to be emphasized that 
DSP is one of the most significantly 
underdiagnosed conditions in the 
United States4. Coupled with the 
lack of practical treatments available, 
providers are failing to meet the pain 
management needs of HIV/AIDS 
patients. It is imperative to find new 
treatment strategies for DSP in order 
to further improve the quality of life 
for HIV/AIDS patients.
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In the United States, more than 1.5 
million people experience traumatic 
brain injury, of which approximately 
75% sustain a mild traumatic brain 
injury (mTBI)1. According to the 
Centers for Disease Control and 
Prevention, mTBIs — also known 
as concussions — are caused by 
blunt force trauma to the head with 
one or more of the following symp-
toms: a period of altered mental 
status, impaired cognitive ability, 
loss of consciousness lasting less 
than 30 minutes, or observed signs 
of neurological or neuropsycho-
logical dysfunction.1 Annual costs 
for injuries related to mTBI total 
nearly $17 billion1. Growing con-
cern about injuries involving motor 
vehicle accidents, sports, and military 
combat have spurred research for 
mTBI1,2,3. However, heterogeneity 
of injuries and study designs have 
made evaluation of mTBI inconsis-
tent2; thus, there is a need to identify 
effective biological markers in brain 
injury to allow for standardization 
in diagnostic criteria and qualities of 
prognosis4. This review aims to con-
solidate and examine existing neural 
biochemical markers that have been 
considered as possible candidates 
in the characterization of mTBI 
for both diagnostic and prognostic 
purposes. 
A literature search was performed 
using PubMed and MEDLINE 
databases, limited to the past 10 
years. Further searches used MeSH 
databases using keywords mTBI, 
serum biomarkers, and traumatic 
brain injury. Manual reviews of 
articles collected were made, exam-
ining candidate markers for mTBI 
with regards to their nature, effec-
tiveness, and timing. Upon review 
of the literature, glial f ibrillary 
acidic protein-breakdown products 
(GFAP-BDP) showed the most 
promising results as a biological 
marker for mTBI. GFAP-BDP was 
detected within one hour post-mTBI, 
and was associated with measures of 
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injury severity as well as focal mass 
lesions4. Ubiquitin carboxy-terminal 
hydrolase (UCH-L1) and alpha-II 
spectrin signature breakdown prod-
ucts (αII spectrin SBDP) require 
further evaluation as viable markers 
for mTBI, yet are more promising 
than older researched markers such 
as S100 protein beta-beta homodimer 
isoform (S100β), cleaved tau protein 
(CTP), and neuron specific enolase 
(NSE), which all show conflicting 
results and inconsistencies in pub-
lished data3,4. The benefits remain 
that the availability of a biochemical 
marker panel for brain injury would 
be similar to those seen in cardiac, 
renal, and hepatic function panels 
and, as such, neural markers play a 
promising and necessary role in the 
characterization of brain injury and 
cost efficiency3. 
This brief review demonstrates 
the deficiency in research of neural 
biomarkers for the evaluation of 
mTBI2,4. Various research groups 
have begun to reevaluate the older 
biomarker candidates with improved 
guidelines, especially S100β, and 
research is ongoing for GFAP-BDP, 
UCH-L1, and αII Spectrin SBDP 
markers. There is a need to fully 
identif y the pathophysiological 
mechanisms of traumatic brain 
injury in order to isolate candidate 
protein markers for the detection 
of injury severity and correlation. 
It is anticipated that a viable neural 
biochemical marker for mTBI will 
be attainable especially with the 
prospect of utilizing GFAP-BDP4. 
There is a need for longitudinal and 
standardized comparison testing 
between all promising neural markers 
for mTBI to increase consistency and 
credibility in data in contrast to pre-
vious independent studies that used 
varying methodologies. Once a viable 
neural biochemical marker has been 
identified, a logical subsequent step 
would be to consider development of 
a protocol for evaluating the utility 
of integration of neural biochemical 
marker assays, neuroimaging studies 
and neurocognitive assessments, 
related to early diagnostic and prog-
nostic indications for mTBI patients. 
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Heterogeneity of injuries and study designs have made 
evaluation of mTBI inconsistent; thus, there is a need 
to identify effective biological markers in brain injury 
to allow for standardization in diagnostic criteria and 
qualities of prognosis.
More than 1.5 million Americans experience 
traumatic brain injuries each year. Computed 
tomography (CT) scans are most commonly 
used soon after an injury to diagnose possible 
life-threatening problems. Magnetic resonance 
imaging (MRI) is used to identify signs of injury 
such as minute bleeding, small areas of bruising, 
or scarring that are invisible on a CT scan.
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The incidence and hospitalizations 
due to skin and soft tissue infections 
(SSTIs) has steadily increased over 
the last decade primarily due to the 
emergence of community acquired 
methicillin resistant Staphylococcus 
aureus (CA-MRSA)1,2. The emer-
gency department (ED) is a common 
site for SSTI treatment and serves 
populations not diagnosed by tra-
ditional surveillance, including the 
homeless and uninsured. However, 
the use of near real-time syndromic 
surveillance within the ED for moni-
toring local epidemiologic trends in 
SSTI presentation where laboratory 
data is unavailable has not been 
previously described. Our study 
sought to describe the epidemiology 
of ED visits for SSTIs in an urban 
setting with diverse neighborhood 
populations using Boston Public 
Health Commission’s Syndromic 
Surveillance System data from 2007 
to 2011. The aims of the study were: 
to demonstrate the use of syndromic 
surveillance data for tracking the 
patterns of SSTIs in an urban popu-
lation; to estimate the burden of ED 
visits associated with SSTIs; and 
to determine potential geographic 
hotspots for SSTIs. 
Final diagnosis International 
Classification of Diseases (ICD-9 
CM) codes for SSTIs, as well as chief 
complaints with SSTI-associated 
words (i.e. abscess, cellulitis), were 
used to define SSTI-related ED 
visits. Identified SSTI visits were 
then mapped to one of 16 Boston 
neighborhoods, each having a unique 
demographic profile with differences 
in race, socioeconomic status, age, 
and population density3. Trends 
within patient demographics were 
examined inside potential hotspots 
of neighborhood clustering for SSTI 
visits in EDs.  
We estimated unique SSTI visits 
to represent 3.29% (n=45,252) of all 
visits to Boston EDs from 2007 to 
2011. During the given time frame, 
the overall yearly percentage of 
SSTI visits increased from 3.08% to 
3.51%. Additionally, we observed a 
seasonal pattern with the peak inci-
dence of SSTI visits occurring in the 
summer. The majority of SSTI visits 
(54%) were among patients 18–44 
years old4. More specifically, males 
accounted for less than half of all 
ED visits for each year of the study 
but accounted for 52% of total SSTI 
visits. Although accounting for only 
24% of Boston’s population,4 African 
American patients accounted for a 
disproportionate 43% of total SSTI 
visits. Furthermore, the five-year 
average rate of SSTI visits for black 
patients (281.2 per 10,000) was 2.8 
times greater [CI 2.7-3.0] than the 
rate for Caucasian patients (99.0 
per 10,000). Overall, the five-year 
average percent of neighborhood-
specific ED visits for SSTIs had a 
geographic distribution ranging from 
a low of 2.69% to a high of 4.11%. 
Our study demonstrates the use of 
syndromic surveillance to track the 
epidemiology of community acquired 
SSTIs through the use of disposi-
tion data. Our results emphasize the 
significant burden of SSTIs in this 
urban population, accounting for up 
to 4% of all ED visits. Additionally, 
our syndromic surveillance methods 
may be useful in providing informa-
tion regarding the local epidemiology 
of SSTIs, including the identification 
of neighborhood hotspots. Local 
syndromic sur veil lance systems 
have the potential to provide public 
health authorities and ED clinicians 
near real-time data on trends in 
demographic risk factors despite an 
unavailability of laboratory data. 
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Iris melanoma is a rare condition, 
comprising 4% of uveal melanoma 
and having a prevalence of 5.1 cases 
per million population in the United 
States1. The mean age of presentation 
is 40–47 years, which is approximately 
10-20 years younger than patients 
with other uveal melanomas2. Most 
patients are Caucasian (97.8%) with 
blue or green irides (97%), and males 
and females are affected equally1,3. 
Pediatric (younger than 21 years 
of age) iris melanoma is especially 
rare, representing only 8% of iris 
melanoma cases1. The differential 
diagnosis of iris melanoma includes 
primary iris cyst (38%), iris nevus 
(31%), essential iris atrophy (5.7%), 
iris foreign body (4.5%), peripheral 
anterior synechiae (2.5%), and iris 
metastasis (2.5%)4. Iris melanoma in 
children is characterized by smaller 
tumors, less seeding, and fewer cases 
of secondary glaucoma compared to 
adults1. 
This report presents a case of 
pediatric iris melanoma to demon-
strate the unavoidable possibility of 
recurrence and complications associ-
ated with iris melanoma in children 
despite standard treatment protocols 
and proper surgical technique. A 
15-year old Caucasian male presented 
with one-month history of a brown 
nodule in the inferotemporal aspect 
of his left eye (Figure A). Iris nevus 
was diagnosed and the patient was 
observed. Nearly two years later the 
lesion had grown in basal diameter 
and thickness (Figure B, C, D), and 
the tumor was excised by partial 
lamellar scleral flap and sector iri-
dectomy (Figure E). Histopathology 
confirmed spindle cell iris melanoma. 
FIGURE 1: A 15-year-old Caucasian male with a pigmented iris lesion. The 
iris lesion was small at presentation (A) and showed growth over 2 years 
(B) visible on gonioscopy (C) and anterior segment optical coherence 
tomography (D). The lesion was excised by partial lamellar scleral flap 
and sector iridectomy (E). Later tumor recurrence in the anterior chamber 
angle with elevated intraocular pressure necessitated Iodine125 plaque 
radiotherapy (F).
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Two years post-operatively, tumor 
recurrence with anterior chamber 
angle involvement and secondary 
glaucoma developed. The pres-
ence of glaucoma in eyes with iris 
melanoma complicates treatment. 
Iris melanoma associated with glau-
coma (compared to iris melanoma 
without glaucoma) is more likely to 
be thicker, involve the angle, and 
demonstrate iris stromal seeding.5 
The patient was then treated with 
custom designed Iodine1,2,5 plaque 
radiotherapy (Figure F). Local tumor 
recurrence after resection in patients 
with iris melanoma ranges from 2% 
to 14%, depending on surgeon and 
surgical technique. The median time 
from resection to recurrence is 45 
months.3 Metastasis after local iris 
melanoma resection occurs in 0% 
to 9% of reported cases3. Older age, 
involvement of the anterior angle, 
elevated IOP, and extraocular exten-
sion are all risk factors for metastasis1. 
Resection and plaque radiotherapy 
for iris melanoma have remarkable 
local success rates but complications 
of therapy can lead to visual damage. 
Visual damage will be an unavoidable 
complication in this case but treat-
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tion of l ife. 
T h i s  c a s e 
re p or t  out-
lines current 
management options for pediatric 
iris melanoma and also demonstrates 
the possibility of tumor recurrence 
that persists despite proper initial 
surgical management. This report 
and further studies on ocular mela-
noma treatment and recurrence will 
serve as invaluable assets to improve 
treatment options with the goal of 
preventing recurrence and mini-
mizing treatment complications. 
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This case report outlines current management 
options for pediatric iris melanoma and 
also demonstrates the possibility of tumor 
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Although the average age of first-year 
medical students is 24, an increasing 
number of mature-age students, 
defined as those over age 30, are 
entering medical school. Most studies 
of mature-age medical students have 
examined academic performance 
using quantitative research design.1 , 
2 Few studies have employed qualita-
tive methodology to determine the 
experience of mature-age medical 
students, especially in the clinical 
setting.
To further study this, a recruit-
ment email was sent to all medical 
students enrolled in clinical rota-
tions. First responders were inter-
viewed until saturation in emerging 
themes was achieved. Interviews 
were conducted and recorded in 
a private office setting, then tran-
scribed. Five mature-age students 
and four traditional students were 
interviewed. Using methodology 
for qualitative research described by 
Mustakas (1994), the investigators 
individually coded the transcripts to 
identify emerging themes.3 Coded 
themes underwent peer review, with 
triangulation of data 
collection, to deter-
mine the main themes. 
Three main themes 
emerged from the 
study. First, abundant 
life experience influ-
ences students’ per-
ception of their role 
on clinical rotations. 
A mature-age student 
explained, “Having 
kids, being married 
and divorced, helps 
in connecting with 
patients.” Previous 
work experience shapes expectations 
as a physician-in-training.
While traditional students tend to 
be intimidated, mature-age students 
desire to take initiative. Age plays a 
role in the students’ ability to relate to 
senior team members, as well as med-
ical school colleagues. Traditional 
students note that mature-age stu-
dents are “more realistic” due to their 
“life experience in the workplace.” 
Mature-age students draw upon pre-
vious life experiences, which shapes 
role expectations, as well as medical 
team dynamics. These differences 
may have implications in training the 
growing number of mature-age med-
ical students. A larger scale qualita-
tive study including multiple medical 
school sites is being developed. 
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A mature-age student explained, 
“Having kids, being married and 
divorced,  helps in connec ting 
with patient s .”  Previous work 
experience shapes expectations as a 
physician-in-training.
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